2021 TOPRA Awards Event
July 27, 2021
Veristat To Sponsor the TOPRA Awards 2021
London - UK 18th November 2021
Orphan Drug Congress Europe | Booth #54
July 9, 2021
Meet Veristat at the Orphan Drug Congress 2021 taking place on 15-18 November 2021, Booth #54
On-Demand Webinar | What's New in Draft MHPD Guidance on Reporting Adverse Reactions for Marketed Products
April 12, 2021
Certus PV, a Veristat Company experts recently lead an Xtalks webinar - View it On-Demand Now
Veristat experts recently led an Xtalks webinar on lessons learned for planning decentralized clinical trials.
Are your risk-management strategies for clinical trials E6 (R2) Compliant? Learn how to be sure.
Webinar Summary
Patient recruitment continues to be the number one reason for study delays. It is estimated for every day a drug is not on the market, $1 million USD is lost in revenue, and more importantly, patients suffering from illnesses are left waiting for products that can help them achieve their health goals or provide a better quality of life.Veristat to Speak on Risk-Based Monitoring At MassBio Forum
September 18, 2019
Join Veristat and panel of experts at the upcoming MassBio Forum:
Veristat to Speak on Successful Sponsor/CRO Partnerships at Evolution Summit Fall 2019
August 29, 2019
Veristat is excited to be heading to the Evolution Summit Fall 2019 taking place on Sept 11-13, 2019 in San Diego, CA. We will be co-hosting a Master Class session on Successful Sponsor/CRO Partnerships.
Webinar | Managing R2 (E6) Compliance As it Relates to Risk
August 2, 2019
Webinar Summary
As of December 2016, the International Council for Harmonisation (ICH) adopted the revised E6 guideline, entitled “Integrated Addendum to Good Clinical Practice (GCP).” The new regulations within E6(R2) require the Sponsor to manage their study using a risk-based approach.